瑞舒伐他汀联合普罗布考对急性脑梗死患者hs-CRP及NO水平的影响  

Effect of rosuvastatin and probucol combination on the level of serum high-sensitivity C-reactive protein and nitric oxide in patients with acute cerebral infarction

作　　者：鞠晓华[1] 张金彪[1] 张海霞[1] 

机构地区：[1]山东威海市立医院神经内科,威海264200

出　　处：《中国实用神经疾病杂志》2011年第19期1-4,共4页Chinese Journal of Practical Nervous Diseases

摘　　要：目的观察瑞舒伐他汀联合普罗布考对急性脑梗死患者血浆超敏C反应蛋白(hs-CRP)及一氧化氮(NO)水平的影响。方法 163例脑梗死急性期患者随机分为4组,A组36例,普通治疗;B组40例,每晚加服瑞舒伐他汀10mg;C组42例,服普罗布考250mg;D组45例,联合服用瑞舒伐他汀和普罗布考,均治疗14d。观察治疗前、治疗后7d、14dhs-CRP、NO的变化等生化指标变化。结果 (1)与治疗前比较,各组治疗后hs-CRP均有下降,差异有统计学意义(P<0.05,P<0.01);B、C、D组hs-CRP下降较A组更明显,差异有统计学意义(P<0.05);治疗后7、14d,D组hs-CRP水平明显低于B、C组,差异有统计学意义(P<0.05)。(2)各组在治疗7d、14dNO较治疗前均有升高,差异有统计学意义(P<0.05);治疗后7d和14d,B、C、D组NO水平高于A组,差异有统计学意义(P<0.05);治疗后14d,D组NO水平明显高于B组、C组,差异有统计学意义(P<0.05)。(3)治疗前hs-CRP与梗死体积显著正相关(r=0.724,P<0.01),与神经功能缺损评分呈正相关(r=0.437,P=0.001)。治疗前NO与梗死体积呈显著负相关(r=-0.797,P<0.01)。结论血浆hs-CRP、NO与急性脑梗死的严重程度密切相关,瑞舒伐他汀、普罗布考能明显降低ACI患者血浆hs-CRP水平,升高NO水平,两药联合应用的疗效优于单药。Objective To study the effect of rosuvastatin and probucol combination on the level of plasma high-sensitivity C-reactive protein （hs-CRP） and nitric oxide （NO） in patients with acute cerebral infartion （ACI）. Methods One hundred and sixty-three patients with acute cerebral infarction were randomly divided into 4 groups： Group A （n= 36）, with basal treat- ment; Group B （n=40）, rosuvastatin 10 mg was added every night; Group C （n：42）, probueol 10 mg was added every morn- ing and night; and Group C（n=45）, rosuvastatin and probucol combination were added. Before the treatment and 7 and 14 days after the treatment, the levels of hs CRP and NO, fasting levels of lipid, such as total cholesterol （TC） and low density lipoproteiwC （LDL-C）, liver functions, creatine kinase（CK）, urea nitrogen, were detected. Neurological function deficit was determined. Results The levels of plasma hs CRP in both four groups after 7 and 14 days treatment were significantly lower than those before treatment（P〈0.05, P〈0.01） ; After treatment, the levels of plasma hs-CRP in B, C, D group were signifi cantly lower than those in A group（P〈0.05）, and D group was significantly lower than B and C group（P〈0.05）. The levels of plasma NO in both four groups after 7 and 14day＇ treatment were significantly higher than those before treatment（P〈0.05） ; After treatment, the levels of plasma NO in B, C, D group were significantly higher than those in A group（ P〈0.05）, and 14 days After treatment, D group was significantly higher than in B and C group（P〈0.05）. The plasma hs-CRP before treatment were positively correlated with the infection volume and neurological function score （ all P〈0.01） ;the plasma NO before treat- ment were negatively correlated with the infection volume and neurological function score （ all P〈0.01）. Conclusion Rosuv- astatin and probueol can significantly decrease the level of serum hs CRP and elevate the plasma level of NO, the combined t

关 键 词：瑞舒伐他汀 普罗布考 急性脑梗死 超敏C反应蛋白 一氧化氮 

分 类 号：R743.33[医药卫生—神经病学与精神病学]